Pfizer
Business & Industry
- Bristol Myers Squibb evolves and expands Standing in the Gaap to advance more equitable care in multiple myeloma
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
- Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
- Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'
- Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis
Research & Development
- Candidate breast cancer drug overloads tumors with "surge" of toxic lipids
- Fighting oral cancer with bioengineered chewing gum
- Millions suffering needlessly with curable hepatitis C
- Targeting the yin and yang of macrophages to strengthen cancer vaccines and anti-tumor immunity
- New knowledge about mobile proteins linked to childhood cancer
- 3D experimental system to evaluate candidate drugs against glioma
- New drug combination doubles down on Alzheimer's treatments
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis